抗感染症薬の世界市場規模、シェア、動向分析レポート：タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測（2025年～2030年）

抗感染症薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗感染症薬の市場規模は、2025年～2030年にCAGR1.61%で拡大し、2030年には1,449億6,000万米ドルに達すると推定されます。

HIV、H1N1、エボラウイルスなどの感染症の流行増加は、ここ数十年の地域社会の行動パターンの大きな変化を反映しています。社会の変化とヘルスケア専門家や患者の意識の高まりが成長を促進しています。

世界保健機関（WHO）や疾病対策予防センター（CDC）などの治療機関は、感染症がもたらす致命的な影響や早期治療の重要性に関する人々の意識を広めることに積極的に取り組んでいます。CDCは、ブラジル、中国、ナイジェリア、インドなどの発展途上国における感染症に対する認識を広め、治療を強化するために、国家保健省（NHM）と協力しています。

しかし、効能・効果を高めた新規治療薬の導入や、市中獲得細菌性肺炎（CABP）の治療薬として2018年にオマダサイクリンが商業化されるなど、パイプライン製品の商業化が、抗感染症薬市場の成長を促進すると予想されます。

抗感染症薬市場レポートのハイライト

• HIV治療薬ビクリビロクのような新しい強力な抗ウイルス薬に関連する高価格のため、2024年の市場シェアは50.9%で抗ウイルス剤が最大セグメントと推定されます。
• 抗ウイルス薬は抗感染症薬市場の重要な構成要素であり、主にウイルス感染の治療と予防に使用されます。
• 2024年8月、塩野義製薬株式会社は、新規のシデロフォア・セファロスポリン系抗生物質であるセフィデロコルの新薬承認申請（NDA）が中国医薬品評価センターにより受理されたと発表しました。セフィデロコルは、多剤耐性株を含むグラム陰性菌を標的とし、第III相試験でイミペネム/シラスタチンと比較して優れた有効性を示しました。
• 2024年には院内薬局が48.5％の最高収益シェアで市場を独占する一方、eコマースは予測期間中に最も急成長するセグメントとなる見込みです。
• 北米は2024年に世界の業界を支配し、全体の収益の38.1%で最大のシェアを占めました。小児と成人の両方における院内感染を含む感染症の高い有病率と、その結果としての抗生物質の過剰使用、処方箋以外の抗感染症薬へのアクセスの増加が主な促進要因です。
• アジア太平洋は、新薬に対するアンメットニーズが高く、ヘルスケアインフラの急速な改善と医療従事者・患者の意識の高まりにより、最も急成長している地域セグメントの一つです。
• 効果的な疾病管理には、新製品開発、M&A、共同開発、事業拡大など、さまざまな長期戦略が必要です。例えば、2024年1月、Basilea PharmaceuticaはSpexis AGからの前臨床抗生物質プログラムの買収を発表しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗感染症薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 抗感染症薬市場分析ツール
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 抗感染症薬市場 - セグメント分析：タイプ別（2018年～2030年）

• 抗感染症薬市場：タイプの変動分析
• タイプ別
  • 抗菌剤
  • 抗ウイルス薬
  • 抗真菌薬

第5章 抗感染症薬市場 - セグメント分析：投与経路別（2018年～2030年）

• 抗感染症薬市場：投与経路の変動分析
• 投与経路別
  • 局所
  • 経口
  • 非経口
  • その他

第6章 抗感染症薬市場 - セグメント分析：流通チャネル別（2018年～2030年）

• 抗感染症薬市場：流通チャネルの変動分析
• 流通チャネル別
  • 院内薬局
  • 小売薬局
  • その他

第7章 抗感染症薬市場：タイプ、投与経路、流通チャネル別の地域の推定・動向分析

• 抗感染症薬市場：地域別展望
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 参入企業
• 参入企業の概要
• 財務実績
• 製品ベンチマーク
• 企業の市場ポジショニング分析：2024年
• 主要企業プロファイル
  • Pfizer Inc.
  • Bayer AG
  • AbbVie
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb
  • Merck &Co., Inc.
  • Sandoz International GmbH
  • B. Braun SE
  • Xellia Pharmaceuticals
  • Mankind Pharma
  • AstraZeneca
  • Boehringer Ingelheim International GmbH

第9章 結論

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 North America Anti-Infective Agents Market, By Country, 2018 - 2030 (USD Million)
• Table 4 North America Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 5 North America Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 6 North America Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 7 U.S. Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 8 U.S. Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 9 U.S. Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 Canada Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 11 Canada Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 12 Canada Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Mexico Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 14 Mexico Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 Mexico Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Europe Anti-Infective Agents Market, By Country, 2018 - 2030 (USD Million)
• Table 17 Europe Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 18 Europe Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 19 Europe Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 UK Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 21 UK Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 22 UK Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 Germany Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 24 Germany Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 25 Germany Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 France Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 27 France Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 28 France Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 Spain Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 30 Spain Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 Spain Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Italy Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 33 Italy Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 34 Italy Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Denmark Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 36 Denmark Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 37 Denmark Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Sweden Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 39 Sweden Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 40 Sweden Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Norway Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 42 Norway Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Norway Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Anti-Infective Agents Market, By Country, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Japan Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 49 Japan Anti-Infective Agents Market, By Route of Administration 2018 - 2030 (USD Million)
• Table 50 Japan Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 China Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 52 China Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 53 China Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 India Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 55 India Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 56 India Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 South Korea Anti-Infective Agents Market, By Type 2018 - 2030 (USD Million)
• Table 58 South Korea Anti-Infective Agents Market, By Route of Administration 2018 - 2030 (USD Million)
• Table 59 South Korea Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Australia Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 61 Australia Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 62 Australia Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Thailand Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 64 Thailand Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 65 Thailand Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Latin America Anti-Infective Agents Market, By Country, 2018 - 2030 (USD Million)
• Table 67 Latin America Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 68 Latin America Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 69 Latin America Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 70 Brazil Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 71 Brazil Anti-Infective Agents Market, By Route of Administration 2018 - 2030 (USD Million)
• Table 72 Brazil Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Argentina Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 74 Argentina Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 75 Argentina Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Middle East & Africa Anti-Infective Agents Market, By Country, 2018 - 2030 (USD Million)
• Table 77 Middle East & Africa Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 78 Middle East & Africa Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 80 South Africa Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 81 South Africa Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 82 South Africa Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 UAE Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 87 UAE Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 88 UAE Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 Kuwait Anti-Infective Agents Market, By Type, 2018 - 2030 (USD Million)
• Table 90 Kuwait Anti-Infective Agents Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 91 Kuwait Anti-Infective Agents Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research approaches
• Fig. 2 Value chain-based sizing & forecasting
• Fig. 3 Market formulation & validation
• Fig. 4 Anti-Infective Agents market segmentation
• Fig. 5 Market driver analysis (current & future impact)
• Fig. 6 Market restraint analysis (current & future impact)
• Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 8 Porter's five forces analysis
• Fig. 9 Anti-Infective Agents market: Type outlook and key takeaways
• Fig. 10 Anti-Infective Agents market: Type movement analysis
• Fig. 11 Antibacterials market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 12 Antivirals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 13 Antifungals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 14 Cephalosporins market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Penicillins market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Fluoroquinolones market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Macrolides market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Carbapenems market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Azoles market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Echinocandins market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Polyenes market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Anti-Infective Agents market: Route of administration outlook and key takeaways
• Fig. 24 Anti-Infective Agents market: Route of administration movement analysis
• Fig. 25 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Anti-Infective Agents market: Distribution channel outlook and key takeaways
• Fig. 28 Anti-Infective Agents market: Distribution channel movement analysis
• Fig. 29 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Research Centers market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 North America Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 U.S. Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Canada Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Mexico Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Europe Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 U.K. Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Germany Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 France Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Italy Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Spain Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Denmark Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Sweden Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Norway Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Asia Pacific Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Japan Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 China Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 India Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Australia Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Thailand Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 South Korea Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Latin America Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Brazil Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Argentina Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 MEA Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 South Africa Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Saudi Arabia Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 UAE Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Kuwait Anti-Infective Agents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 List of key emerging company's/disruptors/innovators

Anti-Infective Agents Market Growth & Trends:

The global anti-infective agents market size is estimated to reach USD 144.96 billion by 2030, expanding at a CAGR of 1.61% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Anti-Infective Agents Market Report Highlights:

• Antiviral was estimated to be the largest segment with a market share of 50.9% in 2024 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
• Antiviral segment dominated the market with a 50.9% share in 2024. Antiviral drugs are crucial components of the anti-infective agents market, primarily used in the treatment and prevention of viral infections
• In August 2024, Shionogi & Co. announced that its New Drug Application (NDA) for cefiderocol, a novel siderophore cephalosporin antibiotic, has been accepted for review in China by the Center for Drug Evaluation. Cefiderocol targets gram-negative bacteria, including multidrug-resistant strains, and has demonstrated superior efficacy in a Phase III trial compared to imipenem/cilastatin.
• Hospital pharmacy dominated the market with the highest revenue share of 48.5% in 2024 while e-commerce is expected to be the fastest-growing segment during the forecast period
• North America dominated the global industry in 2024 and accounted for the largest share of 38.1% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
• Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
• Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in January 2024, Basilea Pharmaceutica announced its acquisition of a preclinical antibiotics program from Spexis AG.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Market Definitions
  • 1.1.2 Estimates And Forecast Timeline
• 1.2 Objectives
  • 1.2.1 Objective - 1
  • 1.2.2 Objective - 2
  • 1.2.3 Objective - 3
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 Gvr's Internal Database
  • 1.4.3 Secondary Sources
  • 1.4.4 Primary Research
• 1.5 Information Or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Epidemiology-Based Market Analysis
    • 1.7.1.1 Approach 1: Epidemiology-Based Approach
    • 1.7.1.2 Approach 2: Commodity Flow Approach
    • 1.7.1.3 Approach 2: Revenue share analysis Using Bottom-up Approach
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Research Assumptions

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 By Type and Route of Administration Snapshot
• 2.3 By Distribution Channel Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Anti-infective Agents Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Ancillary Market Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing Incidence Of Targeted Diseases
    • 3.2.1.2 Growing Investments On R&D Activities Of Anti-Infective Drugs
    • 3.2.1.3 Rise In Initiatives For The Awareness Of Infectious Diseases
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Emergence of Resistance to Anti-infective Drugs and Adverse Effects Associated with them
• 3.3 Anti-infective Agents Market Analysis Tools
  • 3.3.1 Porter's Five Forces Analysis
  • 3.3.2 Pestle Analysis

Chapter 4 Anti-infective Agents Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)

• 4.1 Anti-infective Agents Market: Type Movement Analysis
• 4.2 Anti-infective Agents Market Estimates & Forecast, By Type (USD Million)
  • 4.2.1 Antibacterials
    • 4.2.1.1 Cephalosporins
    • 4.2.1.2 Penicillin
    • 4.2.1.3 Fluoroquinolones
    • 4.2.1.4 Macrolides
    • 4.2.1.5 Carbapenem
    • 4.2.1.6 Others
  • 4.2.2 Antivirals
  • 4.2.3 Antifungals
    • 4.2.3.1 Azoles
    • 4.2.3.2 Echinocandins
    • 4.2.3.3 Polyenes
    • 4.2.3.4 Others

Chapter 5 Anti-infective Agents Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)

• 5.1 Anti-infective Agents Market: Route of Administration Movement Analysis
• 5.2 Anti-infective Agents Market Estimates & Forecast, By Route of Administration (USD Million)
  • 5.2.1 Topical
  • 5.2.2 Oral
  • 5.2.3 Parental
  • 5.2.4 Others

Chapter 6 Anti-infective Agents Market - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Anti-infective Agents Market: Distribution Channel Movement Analysis
• 6.2 Anti-infective Agents Market Estimates & Forecast, By Distribution Channel (USD Million)
  • 6.2.1 Hospital Pharmacies
  • 6.2.2 Retail Pharmacies
  • 6.2.3 Others

Chapter 7 Anti-infective Agents Market: Regional Estimates and Trend Analysis by Type, Route of Administration, and Distribution Channel

• 7.1 Anti-infective Agents Market: Regional Outlook
• 7.2 North America
  • 7.2.1 North America Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 Key Country Dynamics
    • 7.2.2.2 U.S. Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2.3 Competitive/Market Scenario
    • 7.2.2.4 Regulatory Framework
    • 7.2.2.5 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Key Country Dynamics
    • 7.2.3.2 Canada Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3.3 Competitive/Market Scenario
    • 7.2.3.4 Regulatory Framework
    • 7.2.3.5 Reimbursement Scenario
  • 7.2.4 Mexico
    • 7.2.4.1 Key Country Dynamics
    • 7.2.4.2 Mexico Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4.3 Competitive/Market Scenario
    • 7.2.4.4 Regulatory Framework
    • 7.2.4.5 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 UK
    • 7.3.2.1 Key Country Dynamics
    • 7.3.2.2 UK Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.3 Competitive/Market Scenario
    • 7.3.2.4 Regulatory Framework
    • 7.3.2.5 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Key Country Dynamics
    • 7.3.3.2 Germany Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3.3 Competitive/Market Scenario
    • 7.3.3.4 Regulatory Framework
    • 7.3.3.5 Reimbursement Scenario
  • 7.3.4 France
    • 7.3.4.1 Key Country Dynamics
    • 7.3.4.2 France Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4.3 Competitive/Market Scenario
    • 7.3.4.4 Regulatory Framework
    • 7.3.4.5 Reimbursement Scenario
  • 7.3.5 Italy
    • 7.3.5.1 Key Country Dynamics
    • 7.3.5.2 Italy Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5.3 Competitive/Market Scenario
    • 7.3.5.4 Regulatory Framework
    • 7.3.5.5 Reimbursement Scenario
  • 7.3.6 Spain
    • 7.3.6.1 Key Country Dynamics
    • 7.3.6.2 Spain Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6.3 Competitive/Market Scenario
    • 7.3.6.4 Regulatory Framework
    • 7.3.6.5 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Key Country Dynamics
    • 7.3.7.2 Denmark Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7.3 Competitive/Market Scenario
    • 7.3.7.4 Regulatory Framework
    • 7.3.7.5 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Key Country Dynamics
    • 7.3.8.2 Sweden Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8.3 Competitive/Market Scenario
    • 7.3.8.4 Regulatory Framework
    • 7.3.8.5 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Key Country Dynamics
    • 7.3.9.2 Norway Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9.3 Competitive/Market Scenario
    • 7.3.9.4 Regulatory Framework
    • 7.3.9.5 Reimbursement Scenario
  • 7.3.10 Rest Of Europe Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.4 Asia Pacific
  • 7.4.1 Asia Pacific Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Key Country Dynamics
    • 7.4.2.2 Japan Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2.3 Competitive/Market Scenario
    • 7.4.2.4 Regulatory Framework
    • 7.4.2.5 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 Key Country Dynamics
    • 7.4.3.2 China Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3.3 Competitive/Market Scenario
    • 7.4.3.4 Regulatory Framework
    • 7.4.3.5 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 Key Country Dynamics
    • 7.4.4.2 India Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4.3 Competitive/Market Scenario
    • 7.4.4.4 Regulatory Framework
    • 7.4.4.5 Reimbursement Scenario
  • 7.4.5 Australia
    • 7.4.5.1 Key Country Dynamics
    • 7.4.5.2 Australia Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5.3 Competitive/Market Scenario
    • 7.4.5.4 Regulatory Framework
    • 7.4.5.5 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Key Country Dynamics
    • 7.4.6.2 Thailand Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6.3 Competitive/Market Scenario
    • 7.4.6.4 Regulatory Framework
    • 7.4.6.5 Reimbursement Scenario
  • 7.4.7 South Korea
    • 7.4.7.1 Key Country Dynamics
    • 7.4.7.2 South Korea Anti-infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7.3 Competitive/Market Scenario
    • 7.4.7.4 Regulatory Framework
    • 7.4.7.5 Reimbursement Scenario
  • 7.4.8 Rest Of Asia Pacific Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5 Latin America
  • 7.5.1 Latin America Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Key Country Dynamics
    • 7.5.2.2 Brazil Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2.3 Competitive/Market Scenario
    • 7.5.2.4 Regulatory Framework
    • 7.5.2.5 Reimbursement Scenario
  • 7.5.3 Argentina
    • 7.5.3.1 Key Country Dynamics
    • 7.5.3.2 Argentina Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3.3 Competitive/Market Scenario
    • 7.5.3.4 Regulatory Framework
    • 7.5.3.5 Reimbursement Scenario
  • 7.5.4 Rest Of Latin America Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6 MEA
  • 7.6.1 MEA Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 Key Country Dynamics
    • 7.6.2.2 South Africa Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2.3 Competitive/Market Scenario
    • 7.6.2.4 Regulatory Framework
    • 7.6.2.5 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Key Country Dynamics
    • 7.6.3.2 Saudi Arabia Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3.3 Competitive/Market Scenario
    • 7.6.3.4 Regulatory Framework
    • 7.6.3.5 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 Key Country Dynamics
    • 7.6.4.2 UAE Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4.3 Competitive/Market Scenario
    • 7.6.4.4 Regulatory Framework
    • 7.6.4.5 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Key Country Dynamics
    • 7.6.5.2 Kuwait Anti-infective Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5.3 Competitive/Market Scenario
    • 7.6.5.4 Regulatory Framework
    • 7.6.5.5 Reimbursement Scenario
  • 7.6.6 Rest Of MEA Anti-Infective Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

• 8.1 Participant Categorization
• 8.2 Participant's Overview
• 8.3 Financial Performance
• 8.4 Product Benchmarking
• 8.5 Company Market Positioning Analysis, 2024
• 8.6 Key Company Profiles
  • 8.6.1. Pfizer Inc.
    • 8.6.1.1. Company overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Product benchmarking
    • 8.6.1.4. Strategic initiatives
  • 8.6.2. Bayer AG
    • 8.6.2.1. Company overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Product benchmarking
    • 8.6.2.4. Strategic initiatives
  • 8.6.3. AbbVie
    • 8.6.3.1. Company overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Product benchmarking
    • 8.6.3.4. Strategic initiatives
  • 8.6.4. Gilead Sciences, Inc.
    • 8.6.4.1. Company overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Product benchmarking
    • 8.6.4.4. Strategic initiatives
  • 8.6.5. Bristol-Myers Squibb
    • 8.6.5.1. Company overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Product benchmarking
    • 8.6.5.4. Strategic initiatives
  • 8.6.6. Merck & Co., Inc.
    • 8.6.6.1. Company overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Product benchmarking
    • 8.6.6.4. Strategic initiatives
  • 8.6.7. Sandoz International GmbH
    • 8.6.7.1. Company overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Product benchmarking
    • 8.6.7.4. Strategic initiatives
  • 8.6.8. B. Braun SE
    • 8.6.8.1. Company overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Product benchmarking
    • 8.6.8.4. Strategic initiatives
  • 8.6.9. Xellia Pharmaceuticals
    • 8.6.9.1. Company overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Product benchmarking
    • 8.6.9.4. Strategic initiatives
  • 8.6.10. Mankind Pharma
    • 8.6.10.1. Company overview
    • 8.6.10.2. Financial performance
    • 8.6.10.3. Product benchmarking
    • 8.6.10.4. Strategic initiatives
  • 8.6.11. AstraZeneca
    • 8.6.11.1. Company overview
    • 8.6.11.2. Financial performance
    • 8.6.11.3. Product benchmarking
    • 8.6.11.4. Strategic initiatives
  • 8.6.12. Boehringer Ingelheim International GmbH
    • 8.6.12.1. Company overview
    • 8.6.12.2. Financial performance
    • 8.6.12.3. Product benchmarking
    • 8.6.12.4. Strategic initiatives

Chapter 9 Conclusion